|
1
|
Reck M, Rodríguez-Abreu D, Robinson AG,
Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe
S, et al KEYNOTE-024 Investigators, : Pembrolizumab versus
chemotherapy for PD-L1 - positive non-small-cell lung cancer. N
Engl J Med. 375:1823–1833. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Herbst RS, Baas P, Kim DW, Felip E,
Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, et al:
Pembrolizumab versus docetaxel for previously treated,
PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010):
A randomised controlled trial. Lancet. 387:1540–1550. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lou Y, Diao L, Cuentas ERP, Denning WL,
Chen L, Fan YH, Byers LA, Wang J, Papadimitrakopoulou VA, Behrens
C, et al: Epithelial-mesenchymal transition is associated with a
distinct tumor microenvironment including elevation of inflammatory
signals and multiple immune checkpoints in lung adenocarcinoma.
Clin Cancer Res. 22:3630–3642. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Takada K, Okamoto T, Shoji F, Shimokawa M,
Akamine T, Takamori S, Katsura M, Suzuki Y, Fujishita T, Toyokawa
G, et al: Clinical significance of PD-L1 protein expression in
surgically resected primary lung adenocarcinoma. J Thorac Oncol.
11:1879–1890. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Johung KL, Yeh N, Desai NB, Williams TM,
Lautenschlaeger T, Arvold ND, Ning MS, Attia A, Lovly CM, Goldberg
S, et al: Extended survival and prognostic factors for patients
with ALK-rearranged non-small-cell lung cancer and brain
metastasis. J Clin Oncol. 34:123–129. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Schuler M, Wu YL, Hirsh V, O'Byrne K,
Yamamoto N, Mok T, Popat S, Sequist LV, Massey D, Zazulina V, et
al: First-line afatinib versus chemotherapy in patients with
non-small cell lung cancer and common epidermal growth factor
receptor gene mutations and brain metastases. J Thorac Oncol.
11:380–390. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ambrogio C, Gómez-López G, Falcone M,
Vidal A, Nadal E, Crosetto N, Blasco RB, Fernández-Marcos PJ,
Sánchez- Céspedes M, Ren X, et al: Combined inhibition of DDR1 and
Notch signaling is a therapeutic strategy for KRAS-driven lung
adenocarcinoma. Nat Med. 22:270–277. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Martin JT, Durbin EB, Chen L, Gal T, Mahan
A, Ferraris V and Zwischenberger J: Nodal upstaging during lung
cancer resection is associated with surgical approach. Ann Thorac
Surg. 101:238–244; discussion 44–45. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kwon Y: Mechanism-based management for
mucositis: Option for treating side effects without compromising
the efficacy of cancer therapy. OncoTargets Ther. 9:2007–2016.
2016. View Article : Google Scholar
|
|
10
|
Chen QY, Jiao DM, Wang J, Hu H, Tang X,
Chen J, Mou H and Lu W: miR-206 regulates cisplatin resistance and
EMT in human lung adenocarcinoma cells partly by targeting MET.
Oncotarget. 7:24510–24526. 2016.PubMed/NCBI
|
|
11
|
Zeng Z, Bo H, Gong Z, Lian Y, Li X, Li X,
Zhang W, Deng H, Zhou M, Peng S, et al: AFAP1-AS1, a long noncoding
RNA upregulated in lung cancer and promotes invasion and
metastasis. Tumour Biol. 37:729–737. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Patnaik A, Rosen LS, Tolaney SM, Tolcher
AW, Goldman JW, Gandhi L, Papadopoulos KP, Beeram M, Rasco DW,
Hilton JF, et al: Efficacy and safety of abemaciclib, an inhibitor
of CDK4 and CDK6, for patients with breast cancer, non-small cell
lung cancer, and other solid tumors. Cancer Discov. 6:740–753.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lou TF, Sethuraman D, Dospoy P, Srivastva
P, Kim HS, Kim J, Ma X, Chen PH, Huffman KE, Frink RE, et al:
Cancer-specific production of N-acetylaspartate via NAT8L
overexpression in non-small cell lung cancer and its potential as a
circulating biomarker. Cancer Prev Res (Phila). 9:43–52. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wu SG, Liu YN, Tsai MF, Chang YL, Yu CJ,
Yang PC, Yang JC, Wen YF and Shih JY: The mechanism of acquired
resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib
in lung adenocarcinoma patients. Oncotarget. 7:12404–12413.
2016.PubMed/NCBI
|
|
15
|
Ahn MJ, Sun JM, Lee SH, Ahn JS and Park K:
EGFR TKI combination with immunotherapy in non-small cell lung
cancer. Expert Opin Drug Saf. 16:465–469. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zheng D, Ye X, Zhang MZ, Sun Y, Wang JY,
Ni J, Zhang HP, Zhang L, Luo J, Zhang J, et al: Plasma EGFR T790M
ctDNA status is associated with clinical outcome in advanced NSCLC
patients with acquired EGFR-TKI resistance. Sci Rep. 6:209132016.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gainor JF, Shaw AT, Sequist LV, Fu X,
Azzoli CG, Piotrowska Z, Huynh TG, Zhao L, Fulton L, Schultz KR, et
al: EGFR mutations and ALK rearrangements are associated with low
response rates to PD-1 pathway blockade in non-small cell lung
cancer (NSCLC): A retrospective analysis. Clin Cancer Res.
22:4585–4593. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bacac M, Fauti T, Sam J, Colombetti S,
Weinzierl T, Ouaret D, Bodmer W, Lehmann S, Hofer T, Hosse RJ, et
al: A novel carcinoembryonic antigen T-cell bispecific antibody
(CEA TCB) for the treatment of solid tumor. Clin Cancer Res.
22:3286–3297. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Valvona CJ, Fillmore HL, Nunn PB and
Pilkington GJ: The regulation and function of lactate dehydrogenase
A: Therapeutic potential in brain tumor. Brain Pathol. 26:3–17.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shiono S and Yanagawa N: Spread through
air spaces is a predictive factor of recurrence and a prognostic
factor in stage I lung adenocarcinoma. Interact Cardiovasc Thorac
Surg. 23:567–572. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Minguet J, Smith KH and Bramlage P:
Targeted therapies for treatment of non-small cell lung cancer -
recent advances and future perspectives. Int J Cancer.
138:2549–2561. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cha YJ, Kim HR, Lee CY, Cho BC and Shim
HS: Clinicopathological and prognostic significance of programmed
cell death ligand-1 expression in lung adenocarcinoma and its
relationship with p53 status. Lung Cancer. 97:73–80. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Park K, Tan EH, O'Byrne K, Zhang L, Boyer
M, Mok T, Hirsh V, Yang JC8 Lee KH, Lu S, et al: Afatinib versus
gefitinib as first-line treatment of patients with EGFR
mutation-positive non-small-cell lung cancer (LUX-Lung 7): A phase
2B, open-label, randomised controlled trial. Lancet Oncol.
17:577–589. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yang JCH, Sequist LV, Zhou C, Schuler M,
Geater SL, Mok T, Hu CP, Yamamoto N, Feng J, O'Byrne K, et al:
Effect of dose adjustment on the safety and efficacy of afatinib
for EGFR mutation-positive lung adenocarcinoma: Post hoc analyses
of the randomized LUX-Lung 3 and 6 trials. Ann Oncol. 27:2103–2110.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhou M, Snedecor BR, Ng CKD and Shen A:
Decreasing lactate level and increasing polypeptide production by
downregulating the expression of lactate dehydrogenase and pyruvate
dehydrogenase kinase. US Patent 9,487,809, Filed November 28 2012.
November 8–2016.
|
|
26
|
Mohammad GH, Olde Damink SW, Malago M,
Dhar DK and Pereira SP: Pyruvate kinase M2 and lactate
dehydrogenase A are overexpressed in pancreatic cancer and
correlate with poor outcome. PLoS One. 11:e01516352016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sørensen CG, Karlsson WK, Pommergaard HC,
Burcharth J and Rosenberg J: The diagnostic accuracy of
carcinoembryonic antigen to detect colorectal cancer recurrence - A
systematic review. Int J Surg. 25:134–144. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Koukourakis MI, Kakouratos C, Kalamida D,
Bampali Z, Mavropoulou S, Sivridis E and Giatromanolaki A:
Hypoxia-inducible proteins HIF1α and lactate dehydrogenase LDH5,
key markers of anaerobic metabolism, relate with stem cell markers
and poor post-radiotherapy outcome in bladder cancer. Int J Radiat
Biol. 92:353–363. 2016. View Article : Google Scholar : PubMed/NCBI
|
